Michael P. Mullane

Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia

Tait D. Shanafelt, Xin V. Wang, Neil E. Kay et al. · New England Journal of Medicine · 2019 · 738 citations · Full text

Medicine, Immunology, Oncology +16

Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019

Veda N. Giri, Karen E. Knudsen, William Kevin Kelly et al. · Journal of Clinical Oncology · 2020 · 279 citations · Full text

Medicine, Genetics, Oncology +17

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

Tait D. Shanafelt, Victoria Wang, Curtis A. Hanson et al. · Blood · 2022 · 237 citations · Full text

Medicine, Immunology, Pharmacotherapy +13

Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial

Tait D. Shanafelt, Victoria Wang, Neil E. Kay et al. · Blood · 2019 · 36 citations

Medicine, Immunology, Oncology +8

Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib

Victoria Wang, Curtis A. Hanson, Renee C. Tschumper et al. · Blood · 2021 · 35 citations · Full text

Medicine, Oncology, Pharmacology +10